The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.
News Medical on MSN
FDA label update expands CAR T access for primary CNS lymphoma
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that ...
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...
We’ve turned survival responses into a black-and-white idea: pathology or wisdom. This is what we miss when we do that, and why it matters for real healing.
Santa Monica, California Monday, February 9, 2026, 12:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results